If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
50
results.
Updated on
15/11/2026 [06:45:00]
Results 25 to 50 of 50
Absstract of: WO2025037284A2
A vaccine and methods of treatment thereof, wherein the vaccine comprises a recombinant Gram-negative bacteria genetically modified to express a first antigen fusion peptide comprising a neoantigen or series thereof, said neoantigen or series thereof associated with a first secretion signal from a double membrane-spanning secretion system and a second antigen fusion peptide comprising a homologous neoantigen or series thereof, associated with a second secretion signal from an outer membrane-spanning secretion system. The Gram-negative bacteria may be further modified for quadmodal transport. Specifically, the fusion peptides include signal peptides are each associated with a Type III (T3SS) and a Type V (T5SS) secretion system.
Absstract of: CN122811060A
本发明公开了一种重组肠炎沙门菌及其构建方法和应用。本发明通过在肠炎沙门菌同时敲除msbB基因和purL基因，获得减毒的重组肠炎沙门菌，并应用于减毒活疫苗的制备。本发明公开的双基因同时缺失的肠炎沙门菌减毒株毒力较野生型肠炎沙门菌显著下降，在宿主体内定殖时间明显缩短，接种后鸡只无不良反应，对强毒力肠炎沙门菌提供良好的保护作用，可有效清除强毒力菌株感染，对雏鸡提供坚实的免疫保护效果。
Absstract of: WO2026194530A1
The present invention belongs to the field of biomedicine. Provided are a composition for treating tumors using attenuated Salmonella and an immune checkpoint inhibitor, and a method for treating tumors. In the present invention, an anti-tumor immune response is activated by means of the combined use of attenuated Salmonella and an immune checkpoint inhibitor, which synergistically improves the inhibitory effect on tumor cells. The present invention exhibits excellent therapeutic effects against malignant tumors for which effective control means are currently lacking, and has broad application prospects.
Absstract of: US20260284172A1
Disclosed are compositions comprising a fusion polypeptide comprising i) a fusion of a needle tip protein or an antigenic fragment thereof and/or a translocator protein or an antigenic fragment thereof from a Type III secretion system (T3SS) of a Gram negative bacteria and ii) the A1 subunit of the labile toxin (LTA1) from enterotoxigenic Escherichia coli or cholera toxin. and methods of their use.
Absstract of: GB2645265A
Provided is a method for testing the in-vitro bactericidal function of a typhoid vaccine immune serum, comprising: testing the in-vitro bactericidal function of a typhoid vaccine immune serum against Salmonella typhi bacteria by means of an opsonophagocytic killing assay, wherein when the phagocytic killing step of the opsonophagocytic killing assay is completed, the Salmonella typhi bacteria having undergone the phagocytic killing step are cultured at the pH of 7.5-9.5. The opsonophagocytic killing assay is applied to Gram-negative Salmonella Typhi bacteria for the first time, and the in-vitro bactericidal levels of typhoid vaccine immune serums are effectively and accurately evaluated.
Absstract of: EP4810124A2
A method of treating cancer includes administering a dose of a chemotherapy agent in combination with a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The dose of the chemotherapy agent is lower than a maximum effective dose of the chemotherapy agent. The combination provides a synergistic reduction in tumor burden when compared to the reduction in tumor burden provided by administration of an equivalent dose of the chemotherapy agent without the composition consisting essentially of attenuated Salmonella typhimurium.
Absstract of: WO2024122796A1
The present invention relates to a pharmaceutical composition containing aspartic acid as an active ingredient for the prevention or treatment of sepsis and sepsis-related diseases. Containing aspartic acid as an active ingredient, the composition according to an aspect can achieve the effect of inducing the secretion of inflammatory cytokines during immune tolerance or suppression. Moreover, this effect can increase the survival rate of sepsis animal models, compared to antibiotic-administered groups, whereby the composition can be advantageously applied to the prevention and/or treatment of sepsis or systemic inflammatory response syndrome associated with immune tolerance or suppression.
Absstract of: US20260276636A1
A method for specifically, rapidly and quantitatively detecting the total viable bacterial count in raw milk, comprises adding a fluorescent probe specific for viable bacteria, a reagent regulating bacterial cell division and a treatment solution to raw milk for a labeling reaction to obtain an initial labeled sample; and detecting particle fluorescent signal in the initial labeled sample using a high-resolution flow cytometer to achieve rapid quantitative detection of the total viable bacterial count; and the total viable bacterial count detected has a good linear correlation with that detected by the traditional plate counting method. The method for rapidly detecting the total viable bacterial count in raw milk can specifically label the viable bacteria in raw milk without being interfered by other biological cells, and the growth activity of the labeled bacteria can be accurately traced to the results of the plate counting method.
Absstract of: US20260274929A1
The invention provides anti-ETEC adhesin protein antibodies and methods of using the same.
Absstract of: US20260272995A1
Salmonella typhimurium comprising a first heterologous nucleic acid encoding a first polypeptide that causes bacterial lysis, a second heterologous nucleic acid encoding a second polypeptide that causes vacuolar lysis, and a third heterologous nucleic acid encoding a virus.
Absstract of: EP4806992A1
0001 Cyclic dinucleotides, which are a type of signaling substance for cancer treatment, are secondary messengers of intracellular events initiated by GPCR activation and act as a stimulator of interferon genes (STING), and thus can have a significant effect on tumor suppression. Meanwhile, when cancer occurs in a subject, angiogenesis and cell growth proceed at a very high rate in the body, and thus an oxygen-deficient environment is created due to incomplete angiogenesis in cancer tissues, which may be very suitable for the proliferation of anaerobic bacteria such as Salmonella sp. strains or E. coli. 0002 Therefore, the present invention relates to a DNA construct into which is introduced a gene for an enzyme that synthesizes a signaling substance for cancer treatment, e.g., a cyclic dinucleotide, or to a strain transformed with a vector comprising the DNA construct. The DNA construct or the strain transformed with a vector comprising the DNA construct, according to the present invention, targets cancer in a subject and then secretes C-di-AMP or C-di-GMP synthase in the surrounding environment of the cancer, and thus can very effectively prevent or treat cancer and, at the same time, can diagnose cancer in real time.
Absstract of: WO2025151964A1
One drawback for using attenuated bacteria in cancer therapy and as vaccine vectors faces several challenges. These include ensuring safety and stability of the attenuated strains, achieving consistent colonization or delivery to the target site, and eliciting a controlled immune response. To address this, the present disclosure relates to systems, methods and genetically modified bacteria having reduced risk of reversing virulence without use of antibiotic markers. For example, the genetically modified bacteria comprises a chromosomal disruption in an auxotrophic gene and in one or more gene(s) involved in phosphate regulation, and a DNA rescue molecule comprising a functional copy of the auxotrophic gene. The genetically modified bacteria are obtained from virulent pathogenic bacteria containing a virulence plasmid.
Absstract of: CN122749776A
本发明公开了一种抗沙门菌多表位融合蛋白及其制备方法和应用。本发明的多表位蛋白及其蛋白作为疫苗SEMV能够同时激活Th1、Th2和Th17型免疫应答，诱导高滴度特异性抗体产生和淋巴细胞增殖，对肠炎沙门菌和鼠伤寒沙门菌均具有交叉保护效力。该蛋白及其制备的疫苗具有安全性高、成分明确、无排毒返强风险等优势，可用于预防禽沙门菌感染。
Absstract of: CN122727021A
本发明属于兽用生物制品技术领域，涉及一种沙门氏菌灭活疫苗的梯度灭活制备方法及其应用。该方法包括菌株培养、梯度灭活、灭活检验、抗原浓缩与乳化等步骤，其中梯度灭活包括：第一阶段向菌液中加入终浓度为0.01%～0.10%的甲醛，于2～8℃条件下处理24～72 h；第二阶段补加甲醛至终浓度为0.10%～0.40%，并升温至30～40℃继续处理12～48 h。所述低温低浓度处理用于对菌体表面抗原表位进行预固定，从而减少后续高浓度甲醛处理对抗原结构的破坏。采用本发明方法制备的灭活疫苗在保证灭活彻底性和生物安全性的同时，可显著提高血清抗体水平及肠道黏膜sIgA水平，适用于鸡、鹅等禽类动物沙门氏菌病的预防。
Absstract of: WO2026185450A1
Novel antibody for antimicrobial resistance detection Antibodies or fragments thereof are provided that specifically bind to bacterial ribosomal subunit S16 and are useful for capturing RNA of a wide-spectrum of bacteria, thereby improving accuracy and speed of antibiotic resistance diagnostics. The antibody or the fragment thereof comprises a heavy-chain variable region CDR1 comprising the amino acid sequence AMS, a heavy-chain variable region CDR2 comprising SEQ ID NO: 16, a heavy-chain variable region CDR3 comprising SEQ ID NO: 18, a light-chain variable region CDR1 comprising SEQ ID NO: 36, a light-chain variable region CDR2 comprising SEQ ID NO: 38 and a light-chain variable region CDR3 comprising SEQ ID NO: 40.
Absstract of: US20260265313A1
The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.
Absstract of: US20260263370A1
The described technology pertains to biotechnology, specifically engineered bacterial systems designed for extracellular delivery of therapeutic proteins in cancer treatment. The disclosed bacteria, such as Salmonella typhimurium, are genetically modified to include plasmid coding for a therapeutic protein, a salicylic acid-inducible promoter operably linked to a lysis protein, and a plasmid retention mechanism. These bacteria are modified to remain extracellular by incorporating knockouts such as flhD, which prevent intracellular invasion of cancer cells. Upon induction with salicylic acid, the bacteria lyse and release therapeutic proteins, such as IFNγ, into the tumor microenvironment, converting the environment from immunosuppressive to immunostimulatory and reducing tumor growth. The system is designed to provide safe and tumor-specific delivery, minimizing systemic toxicity. Applications include treating solid tumors, such as pancreatic and breast cancer.
Absstract of: WO2026187809A2
Provided herein are compounds that target Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Salmonella typhimurium, and are selective over Gram-negative and Gram-positive commensal bacteria, as well as their methods of use.
Absstract of: WO2026185254A1
The present invention relates to an attenuated Salmonella strain, particularly a Salmonella typhi Ty21a strain comprising a recombinant DNA molecule comprising at least one eukaryotic expression cassette encoding a fusion protein comprising a targeting unit, a multimerization unit, and an antigenic unit and to a pharmaceutical composition comprising said attenuated Salmonella strain, wherein the composition is for oral administration. Said attenuated Salmonella strain or pharmaceutical composition is further provided for use in preventing and/or treating a disorder or disease selected from the group consisting of cancer, an infectious disease a chronic infectious disease or an autoimmune disease.
Absstract of: US20260262663A1
Systems and methods of decontaminating food substances by using cold plasma to enhance the performance of ionized hydrogen peroxide to decontaminate food, and methods of use thereof. Cold plasma activation significantly enhanced the efficacy of hydrogen peroxide mist against bacteria on fresh produce, and the technology may be used to enhance microbial safety. Cold plasma activated ionized hydrogen peroxide (iHP) can be applied on various fresh produce items. In particular, cold plasma enhanced the efficacy of hydrogen peroxide (H2O2) mist against Salmonella.
Absstract of: US20260263534A1
The present disclosure provides a method of treating a solid tumor cancer. The method includes administering a combination to a subject in need thereof. The combination includes at least two chemotherapy agents and a dose of a composition consisting essentially of attenuated Salmonella typhimurium. The present disclosure also provides an anti-tumor agent for use in a method of treating cancer. In such instances, the anti-tumor agent may include the combination.
Absstract of: WO2026184777A1
A Lactobacillus plantarum strain having an antibacterial effect, and the use thereof, wherein the Lactobacillus plantarum has a deposit number of CGMCC No. 33151. The strain exhibits strong tolerance to bile salts and resists gastric acid, and has good acid producing and H2O2-producing capabilities, has a relatively strong antibacterial effect against common pathogenic bacteria such as Staphylococcus aureus, Candida albicans, Escherichia coli, Salmonella and Helicobacter pylori, and is capable of inhibiting urease activity, interfering with Helicobacter pylori colonization, etc. to inhibit Helicobacter pylori infection or alleviate the symptoms of Helicobacter pylori infection, and reduce the disease severity of colitis in mice. The strain can be used in the preparation of a microbial preparation, and has the potential for use in the preparation of a drug for preventing and/or treating diseases caused by Helicobacter pylori infection.
Absstract of: CN122705692A
本发明提供了一种能响应温度变化从而诱导下游基因表达的重组盐单胞菌及其构建方法和应用。所述重组盐单胞菌利用突变筛选得到的Toll/白介素‑1受体类似蛋白A(TIR‑like protein A,TlpA)构建的37°C及42°C诱导型启动子，并且对该37°C及42°C诱导型启动子进行了全面表征。所述重组盐单胞菌可以实现在30°C升温至37°C及37°C升温至42°C时启动目的基因表达的目的，且采用这种方法实现基因的诱导表达，具有操作简单、成本低的特点。
Absstract of: WO2026180700A1
The present invention provides a modified quorum sensing circuit, wherein the modified quorum sensing circuit comprises a quorum sensing synthase and a quorum sensing receptor, wherein the quorum sensing synthase and the quorum sensing receptor are transcriptionally separated.
Nº publicación: US20260256858A1 03/09/2026
Applicant:
PSYCHED WELLNESS LTD [CA]
Psyched Wellness Ltd.
Absstract of: US20260256858A1
0000 Disclosed herein are processes for extracting muscimol from Amanita mushrooms, and more particularly, from Amanita muscaria, including processes that increase muscimol content and decrease ibotenic acid content, and further including improved processes that produce extract at scale, such as at kilogram scale. In some aspects are methods for selecting Amanita mushroom biomass suitable for the disclosed extraction methods, so as to produce extracts and products that are safe and beneficial for human use. Also disclosed are numerous compositions and formulations made with disclosed extracts, including beverage formulations, having a variety of improvements and advantages over previously known products made from Amanita muscaria.
BOPI
Electronic site
